Summary

Acute Agitation and Aggression Treatment Market – Scope of Report
TMR’s report on the global acute agitation and aggression treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global acute agitation and aggression treatment market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute agitation and aggression treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the acute agitation and aggression treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global acute agitation and aggression treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global acute agitation and aggression treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global acute agitation and aggression treatment market.

The report delves into the competitive landscape of the global acute agitation and aggression treatment market. Key players operating in the global acute agitation and aggression treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global acute agitation and aggression treatment market profiled in this report.

Key Questions Answered in Global acute agitation and aggression treatment Market Report
• What is the sales/revenue generated by acute agitation and aggression treatment across all regions during the forecast period?
• What are the opportunities in the global acute agitation and aggression treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Acute Agitation and Aggression Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global acute agitation and aggression treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global acute agitation and aggression treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global acute agitation and aggression treatment market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Agitation and Aggression Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, 2020-2034
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Treatment Protocol
5.2. Key Strategies adopted by Market Players
5.3. Mental Health Spendings by Countries
5.4. Healthcare Industry Overview
5.5. PESTEL Analysis
5.6. PORTER's Five Forces Analysis
5.7. Pipeline Analysis
5.8. Regulatory Scenario Assessment
5.9. Reimbursement Scenario by Key Countries
5.10. Epidemiology of Acute Agitations and Aggression Disorders
5.11. Supply Chain Analysis
5.12. Key Industry Events
6. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Treatment Approach
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Approach, 2020-2034
6.3.1. First-Generation Anti-Psychotics:
6.3.1.1. Chlorpromazine
6.3.1.2. Haloperidol
6.3.2. Second-Generation Anti-Psychotics
6.3.2.1. Quetiapine
6.3.2.2. Olanzapine
6.3.2.3. Ziprasidone
6.3.3. Benzodiazepines
6.3.3.1. Lorazepam
6.3.3.2. Midazolam
6.3.4. Alpha-2 Adrenergic Agonist
6.3.4.1. Clonidine
6.3.4.2. Dexmedetomidine
6.3.5. Others
6.4. Market Attractiveness Analysis, by Treatment Approach
7. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2020-2034
7.3.1. Alcohol Withdrawal
7.3.2. Bipolar Disorder
7.3.3. Dementia
7.3.4. Depression
7.3.5. Drug-induced agitation and aggression
7.3.6. Schizophrenia
7.3.7. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Acute Agitation and Aggression Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Approach, 2020-2034
10.2.1. First-Generation Anti-Psychotics:
10.2.1.1. Chlorpromazine
10.2.1.2. Haloperidol
10.2.2. Second-Generation Anti-Psychotics
10.2.2.1. Quetiapine
10.2.2.2. Olanzapine
10.2.2.3. Ziprasidone
10.2.3. Benzodiazepines
10.2.3.1. Lorazepam
10.2.3.2. Midazolam
10.2.4. Alpha-2 Adrenergic Agonist
10.2.4.1. Clonidine
10.2.4.2. Dexmedetomidine
10.2.5. Others
10.3. Market Value Forecast, by Indication, 2020-2034
10.3.1. Alcohol Withdrawal
10.3.2. Bipolar Disorder
10.3.3. Dementia
10.3.4. Depression
10.3.5. Drug-induced agitation and aggression
10.3.6. Schizophrenia
10.3.7. Others
10.4. Market Value Forecast, by Distribution Channel, 2020-2034
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2020-2034
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Approach
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Acute Agitation and Aggression Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Approach, 2020-2034
11.2.1. First-Generation Anti-Psychotics:
11.2.1.1. Chlorpromazine
11.2.1.2. Haloperidol
11.2.2. Second-Generation Anti-Psychotics
11.2.2.1. Quetiapine
11.2.2.2. Olanzapine
11.2.2.3. Ziprasidone
11.2.3. Benzodiazepines
11.2.3.1. Lorazepam
11.2.3.2. Midazolam
11.2.4. Alpha-2 Adrenergic Agonist
11.2.4.1. Clonidine
11.2.4.2. Dexmedetomidine
11.2.5. Others
11.3. Market Value Forecast, by Indication, 2020-2034
11.3.1. Alcohol Withdrawal
11.3.2. Bipolar Disorder
11.3.3. Dementia
11.3.4. Depression
11.3.5. Drug-induced agitation and aggression
11.3.6. Schizophrenia
11.3.7. Others
11.4. Market Value Forecast, by Distribution Channel, 2020-2034
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Approach
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Acute Agitation and Aggression Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Approach, 2020-2034
12.2.1. First-Generation Anti-Psychotics:
12.2.1.1. Chlorpromazine
12.2.1.2. Haloperidol
12.2.2. Second-Generation Anti-Psychotics
12.2.2.1. Quetiapine
12.2.2.2. Olanzapine
12.2.2.3. Ziprasidone
12.2.3. Benzodiazepines
12.2.3.1. Lorazepam
12.2.3.2. Midazolam
12.2.4. Alpha-2 Adrenergic Agonist
12.2.4.1. Clonidine
12.2.4.2. Dexmedetomidine
12.2.4.3. Guanabenz
12.2.5. Others
12.3. Market Value Forecast, by Indication, 2020-2034
12.3.1. Alcohol Withdrawal
12.3.2. Bipolar Disorder
12.3.3. Dementia
12.3.4. Depression
12.3.5. Drug-induced agitation and aggression
12.3.6. Schizophrenia
12.3.7. Others
12.4. Market Value Forecast, by Distribution Channel, 2020-2034
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & Newzealend
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Approach
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Acute Agitation and Aggression Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Approach, 2020-2034
13.2.1. First-Generation Anti-Psychotics:
13.2.1.1. Chlorpromazine
13.2.1.2. Haloperidol
13.2.2. Second-Generation Anti-Psychotics
13.2.2.1. Quetiapine
13.2.2.2. Olanzapine
13.2.2.3. Ziprasidone
13.2.3. Benzodiazepines
13.2.3.1. Lorazepam
13.2.3.2. Midazolam
13.2.4. Alpha-2 Adrenergic Agonist
13.2.4.1. Clonidine
13.2.4.2. Dexmedetomidine
13.2.4.3. Guanabenz
13.2.5. Others
13.3. Market Value Forecast, by Indication, 2020-2034
13.3.1. Alcohol Withdrawal
13.3.2. Bipolar Disorder
13.3.3. Dementia
13.3.4. Depression
13.3.5. Drug-induced agitation and aggression
13.3.6. Schizophrenia
13.3.7. Others
13.4. Market Value Forecast, by Distribution Channel, 2020-2034
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Approach
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Acute Agitation and Aggression Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Approach, 2020-2034
14.2.1. First-Generation Anti-Psychotics:
14.2.1.1. Chlorpromazine
14.2.1.2. Haloperidol
14.2.2. Second-Generation Anti-Psychotics
14.2.2.1. Quetiapine
14.2.2.2. Olanzapine
14.2.2.3. Ziprasidone
14.2.3. Benzodiazepines
14.2.3.1. Lorazepam
14.2.3.2. Midazolam
14.2.4. Alpha-2 Adrenergic Agonist
14.2.4.1. Clonidine
14.2.4.2. Dexmedetomidine
14.2.4.3. Guanabenz
14.2.5. Others
14.3. Market Value Forecast, by Indication, 2020-2034
14.3.1. Alcohol Withdrawal
14.3.2. Bipolar Disorder
14.3.3. Dementia
14.3.4. Depression
14.3.5. Drug-induced agitation and aggression
14.3.6. Schizophrenia
14.3.7. Others
14.4. Market Value Forecast, by Distribution Channel, 2020-2034
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2020-2034
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Treatment Approach
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Eli Lilly and Company
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Pfizer, Inc.
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. GlaxoSmithKline
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. Johnson & Johnson
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Teva Pharmaceutical Industries Ltd.
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Amneal Pharmaceuticals LLC
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. F. Hoffmann-La Roche Ltd
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Bausch Health Companies, Inc.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Apotex, Inc.
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments